
Antibiotics
Latest News

Latest Videos

More News

AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.

A new meta-analysis finds alarming increases in colistin resistance among Acinetobacter baumannii and Pseudomonas aeruginosa across Africa, threatening the effectiveness of one of the last-resort antibiotics.

The World Health Organization has released 3 new target product profiles aimed at guiding the development of urgently needed antibiotics for severe drug-resistant infections, including multidrug-resistant gram-negative infections, resistant gram-positive infections in vulnerable patients, and bacterial meningitis.

Peptilogics has enrolled the first patient in its RETAIN trial evaluating PLG0206, a first-in-class anti-biofilm therapy designed to treat prosthetic joint infections.

Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.

In 2025, the Infectious Diseases Society of America published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overview of the risk assessment and antibiotic treatment of GAS pharyngitis.

Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides/polymyxins and comparable to ceftazidime-avibactam.

This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.

The Centers for Disease Control and Prevention (CDC) characterizes epidemiology, serotype and treatment resistance of extraintestinal invasive Escherichia coli, the most common pathogen in community-onset sepsis.

A large international study published in The Lancet shows that obesity substantially increases the risk of severe illness and death from most infectious diseases, potentially accounting for more than 10% of infection-related deaths worldwide.

This week, listen in on commentary around the ongoing measles outbreak, read our new Antibiotics Deconstructed column on IV fosfomycin, review data on metformin preventing long COVID, insights on diagnostic stewardship, and more.

The FDA recently approved intravenous fosfomycin (Contepo), which is a new option for adults with complicated urinary tract infections, including those caused by resistant Gram-negative pathogens. Here is an overview of the therapeutic including its mechanism of action, data, availability, and prospective costs.

This is the fourth time the antimicrobial bill looking at a subscription-payment model has been introduced in the Congress and has some updates in how these therapeutics are developed and paid for with help from the federal government.

A global review finds growing antimicrobial resistance among the main bacteria causing meningitis—especially in low- and middle-income countries—raising concerns about the continued effectiveness of standard treatments and the urgent need for stronger surveillance.

MicuRx Pharmaceuticals has received FDA clearance to begin a phase 2a clinical trial of MRX-5, a novel oral antibacterial therapy for patients with Mycobacterium abscessus pulmonary disease.

This week, read about the latest number of confirmed cases of measles in the US, novel findings around UTI treatment failure, an overview of zoliflodacin and gepotidacin, and more.

Fedora Pharmaceuticals is presenting new preclinical data at the IMARI conference demonstrating that its lead candidate, FPI-2119, shows strong activity against some of the most dangerous drug-resistant Gram-negative infections, supporting its advancement toward clinical trials.

This past December, the FDA approved both zoliflodacin and gepotidacin for this sexually transmitted infection marking a significant advance amid rising antibiotic resistance. Here is an overview of the antibiotics.

This week, read about the CDC's analysis on the continuing burden of COVID-19 on a certain population, watch an Emory nurse provide an overview of donning and doffing personal protective equipment when caring for patients with high-consequence infectious disease, a review of diagnostics and treatments for invasive candidiasis, and more.

The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.

This week, read articles from our recent issue on topics including invasive fungal disease in transplantation, lenacapavir's role in PrEP, antimicrobial treatment around non–carbapenemase-producing carbapenem-resistant enterobacterales, and more.

Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.












































































































































































